RXST
RxSight, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.05
P/S
2.15
EV/EBITDA
-7.08
DCF Value
$-251.96
FCF Yield
0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.6%
Operating Margin
-35.8%
Net Margin
-29.0%
ROE
-14.0%
ROA
-12.5%
ROIC
-16.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $32.6M | $-9.2M | $-0.22 |
| FY 2025 | $134.5M | $-38.9M | $-0.95 |
| Q3 2025 | $30.3M | $-9.8M | $-0.24 |
| Q2 2025 | $33.6M | $-11.8M | $-0.29 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.21
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.